Centre For Research Excellence In Cervical Cancer Control (C4)
Funder
National Health and Medical Research Council
Funding Amount
$2,486,383.00
Summary
Cervical cancer remains common globally despite over 50 years of Pap testing. Australia led the world in HPV vaccination and in 2017 will be the first to deliver a national screening program based on HPV testing. Our CRE, led by cervical cancer prevention experts at CCNSW,VCS, and Kirby, will marry cross-disciplinary research and evaluation of HPV vaccination and screening to provide solid evidence about these new approaches with a view to ultimately reducing the global burden of this cancer.
Skin cancers, including melanoma, present a significant health, social and economic burden in Australia. Despite the rising incidence of melanoma, the most deadly form of skin cancer, there is currently no national or population-based screening program available. The aim of this CRE is to identify how novel skin imaging technologies can be integrated into the pathway to improve early detection, and ultimately reduce the health and economic burden caused by melanoma skin cancer.
Creating Sustainable Healthcare: Ensuring New Diagnostics Avoid Harms, Improve Outcomes, And Direct Resources Wisely
Funder
National Health and Medical Research Council
Funding Amount
$2,497,658.00
Summary
Novel imaging, biomarkers and genomic tests for risk assessment and early detection are emerging as major forces for change in clinical practice. While providing advances and new benefits for patients, new technologies can also have harmful, unintended consequences - overdiagnosis and overtreatment. This multidisciplinary CRE will investigate how to respond to emerging technologies to optimise health outcomes while avoiding harms and directing healthcare resources wisely.
Bowel cancer, the second most diagnosed and cause of cancer death is preventable. Low risk people need no screening or just inexpensive fecal occult blood tests. Increased risk people need the more expensive and invasive colonoscopies. There is overuse of colonoscopy by those at low risk and underuse by those at high risk. Our Centre brings together scientists, epidemiologists and clinicians to develop a personalised risk tool and methods to implement the tool to increase appropriate screening.